Balkwill and collaborators demonstrated that neutralization of TNFα during early stages of skin carcinogenesis is sufficient to inhibit tumor formation and set the basis of the rationale of anti-TNFα therapy for cancer treatment [185]. The gene discussed is TNF; the disease is neoplasm.